“Thanks for the approval notice! It’s my pleasure to work with your team.”

Case Summary:

With a PhD. in pharmaceutical sciences, our client sought our law firm’s assistance in preparing her I-140 NIW (National Interest Waiver) and I-140 EB-1A (Alien of Extraordinary Ability) petitions. We began by evaluating the breadth of her expertise and accomplishments in the field. Impressed by the credentials, we promptly finalized the client-attorney agreement and committed to supporting her application.

In her petition packet, we highlighted her significant contributions and proven success in pharmaceutical sciences:

• We summarized her research which advanced cancer therapy with polymeric drugs. Her sophisticated investigations of cancer treatment have yielded novel methods and original discoveries, resulting in her status as an authority in the field.
• In addition, we highlighted her strong publication record, which includes 26 peer-reviewed journal articles (5 first- or co-first-authored) and 1 book chapter. These works have been featured in highly ranked, peer-reviewed journals and conferences recognized for their rigorous standards and focus on impactful research.
• Her work has been cited 1,191 times, underscoring her influence on independent researchers both in the United States and internationally.
• Due to her recognized expertise, she has been invited to serve as a peer reviewer for multiple journals and conferences. We verified that our client judged the work of others at least 12 times and her peer review service thus reflects well on her abilities as a researcher and the expert position he holds among her professional peers.
• Furthermore, her work has received funding from various prestigious organizations, such as the National Institutes of Health, the National Science Foundation, and the Welch Foundation.
• To strengthen her case, we also included recommendation letters from four internationally renowned experts in pharmaceutical sciences, all attesting to her groundbreaking research and exceptional contributions to the field. One of the excerpts is mentioned below:

“[Client’s] novel approach advances the efficacy of existing treatments while reducing toxicity, ultimately meeting critical needs in current therapeutic options, and supporting economic growth within the pharmaceutical industry by expanding opportunities for drug development. [Client’s] research contributes to improving patient outcomes and quality of life for millions of Americans by targeting major public health issues like cancer and IBD. This gives her research strategic significance for the nation’s pharmaceutical and biomedical sectors, positioning the United States as a leader in innovative drug delivery systems and personalized medicine.”

Based on these expert testimonials and supporting evidence, we implore the USCIS to recognize our client’s unique expertise and the significant impact of her work, reinforcing the expectation that she will continue making substantial contributions within the United States.

In conclusion, we are delighted that her NIW petition was approved in just 7 days and her EB1A petition was approved in 6 days after filing under the enhanced premium processing service. We appreciate her cooperation with our legal team throughout the process and are grateful for the opportunity to share her remarkable success story.